Last reviewed · How we verify
NCT06951321
Characteristics of Postinfectious Cough
trial in Cough in 1,650 participants. Completed in 1 April 2025.
1 April 2025
Quick facts
| Lead sponsor | Kefang Lai |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,650 |
| Start date | 1 March 2023 |
| Primary completion | 1 April 2025 |
| Estimated completion | 1 April 2025 |
| Sites | 1 location across China |
Conditions studied
- Cough — all drugs for Cough →
Sponsor
Kefang Lai
Who can join
Adults 18 to 70, any sex, with Cough. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Collect the age, sex and other demographic data of 1600 patients with chronic cough after COVID-19 infection and clinical parameters such as cough characteristics, establish a cohort of patients with chronic cough after COVID-19 infection, observe the type and level of airway inflammation, airway responsiveness, cough sensitivity and changes in microbiology of patients with chronic cough after COVID-19 infection, clarify the epidemiological characteristics, clinical pathophysiological characteristics, long-term prognosis and related factors of patients with chronic cough after COVID-19 infection, explore the clinical pathophysiological characteristics and pathogenesis of cough after COVID-19 infection, and provide a theoretical basis for the treatment of persistent cough after COVID-19 infection.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Long-Term Prognosis of Adult Patients with Persistent Cough Post COVID-19 and Its Risk Factors: A Nationwide Prospective Study.
He W, Zhang J, Sun D, Yi F, et al · · 2026 · PMID 41848877 · DOI 10.1007/s00408-026-00879-x
Verify or expand the search:
- PubMed search for NCT06951321
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cough
Currently open trials in the same condition.
- NCT07171099 — Efficacy and Safety of Rengalin in the Treatment of ARVI Cough in Children · Phase 3 · recruiting
- NCT06999577 — The Mechanism Versus PPI Trial · Phase 4 · recruiting
- NCT06979141 — Dexmedetomidine, Magnesium Sulphate and Lidocaine for Cough Suppression After General Anesthesia · Phase 3 · recruiting
- NCT06918756 — Development of a Cough Control Questionnaire (CCQ) · recruiting
- NCT06878209 — Cough and Hemorrhoids · recruiting
Other Kefang Lai trials
Trials by the same sponsor.
- NCT05265871 — ATP Level and Cough Sensitivity to ATP in Subjects With Refractory/Unexplained Chronic Cough · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06951321 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kefang Lai
- Last refreshed: 30 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06951321.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing